.svg)
The Antibody Panel That Flags a Gluten-Triggered Autoimmune Response
A Celiac Disease Comprehensive Panel is a blood test that looks for specific immune flags—antibodies—that your body can produce when gluten triggers an autoimmune reaction. These antibodies are made by B cells in the intestinal immune system and spill into the bloodstream. The panel commonly includes antibodies to tissue transglutaminase (tTG IgA, sometimes IgG), endomysial antibodies (EMA), and deamidated gliadin peptides (DGP), along with a check of total immunoglobulin A (IgA) to make sure the results are interpretable.
This panel reflects the body's targeted immune response to gluten and to the enzyme tissue transglutaminase in the small intestine. When these antibodies are present, they signal that gluten exposure is engaging adaptive immunity in a way characteristic of celiac autoimmunity, a process that can inflame and injure the small intestinal lining (mucosal villi). Together, these markers help reveal whether the immune system is expressing the pattern specific to celiac disease and can be used to follow the quieting of that response when gluten is removed from the diet.
Linking Gut Integrity to Whole-Body Nutrient Health
The Celiac Disease Comprehensive Panel gauges whether your immune system is mounting an autoimmune response to gluten that damages the small intestine. By measuring celiac‑specific antibodies (such as tissue transglutaminase and endomysial) alongside total IgA, it connects gut integrity with nutrient absorption, blood health, bone strength, skin, nerves, and even fertility and growth.
Big picture: this panel integrates immune tolerance with gut surface area and micronutrient delivery to every organ. Detecting antibody activity helps explain anemia, osteoporosis, neuropathic symptoms, and growth issues, and it clarifies long‑term risks such as fractures and, rarely, intestinal lymphoma if disease remains active.
Negative, Borderline, or Positive — How to Read the Titers
In general, antibody results are interpreted against a lab cutoff as negative, borderline, or positive; for these antibodies, within reference ranges values sit at the negative end. Total IgA is ideally in the mid‑normal range to help support that antibody tests are reliable.
When celiac‑specific antibodies are low or negative, this usually reflects immune tolerance to gluten or well‑controlled disease, with intact villi and efficient absorption. However, if total IgA is low, it can mask antibody signals. Selective IgA deficiency itself can bring recurrent sinus or respiratory infections and is more common alongside autoimmune conditions. The main exception is selective IgA deficiency: if total IgA is low, IgA-based results (tTG-IgA, EMA) can appear falsely low, so IgG-based markers in the panel carry more weight.
Being in range suggests negative celiac serology with a normal total IgA, pointing to stable nutrient absorption, lower systemic inflammatory signaling, and resilient gut-immune function. For most people, the optimal pattern is fully negative rather than borderline near the cutoff.
When celiac antibodies are elevated, they signal active autoimmune activity against intestinal villi, leading to malabsorption. People may notice bloating, diarrhea or constipation, weight change, fatigue, iron‑deficiency anemia, mouth ulcers, dermatitis herpetiformis, bone loss, or neuropathy. Children may show poor growth or delayed puberty. Women can experience menstrual irregularities, subfertility, or adverse pregnancy outcomes. Celiac often clusters with autoimmune thyroid disease and type 1 diabetes. Higher titers tend to track with greater mucosal injury.
What Can Distort a Celiac Antibody Result
Notes: Accurate interpretation requires adequate gluten exposure before testing. Young children and people with IgA deficiency may show different antibody patterns. Liver disease, infections, and other autoimmune conditions can cause false positives. Assay cutoffs vary by lab, and intestinal biopsy remains the diagnostic standard when serology is positive or equivocal.
FAQs
The Celiac Disease Comprehensive Panel is a group of blood tests designed to detect the body’s immune response to gluten, a protein found in wheat, barley, and rye. It measures specific antibodies—such as tissue transglutaminase (tTG) IgA, endomysial antibody (EMA), and deamidated gliadin peptide (DGP) IgA/IgG—produced when the immune system reacts abnormally to gluten. The panel also checks total IgA levels to identify IgA deficiency, which can mask celiac disease. By evaluating these markers, the panel helps aid in evaluation of celiac disease, monitor gluten-free diet adherence, and guide further testing like endoscopy or small-bowel biopsy if needed.
The panel detects antibodies that the immune system produces in response to gluten exposure in genetically susceptible individuals. Elevated levels of tTG, EMA, or DGP antibodies indicate an active autoimmune response damaging the small intestine’s lining. The presence and pattern of these antibodies, along with total IgA status, help confirm or rule out celiac disease. If antibody levels are high, further confirmation with a small-bowel biopsy may be recommended. The panel is accurate when the patient is consuming gluten at the time of testing.
The main antibodies measured include tissue transglutaminase (tTG) IgA, endomysial antibody (EMA), and deamidated gliadin peptide (DGP) IgA and IgG. These antibodies target gluten-related proteins and the gut lining, signaling an autoimmune reaction. The panel also measures total IgA to check for IgA deficiency, which can affect test accuracy. Some panels may include HLA-DQ2/DQ8 genetic testing to assess genetic susceptibility to celiac disease.
Total IgA is measured because most celiac-specific antibodies are of the IgA class. If a person has IgA deficiency, these antibodies may be falsely low or undetectable, leading to missed diagnosis. IgA deficiency itself can cause recurrent infections and is more common in children. If IgA deficiency is found, the panel pivots to measuring IgG-based antibodies (like DGP IgG) to helps support accurate detection of celiac disease.
Doctors may order the panel for persistent symptoms such as bloating, diarrhea, constipation, fatigue, anemia, weight loss, or mouth ulcers. It is also indicated for unexplained nutrient deficiencies (iron, vitamin D, calcium), osteoporosis, poor growth in children, delayed puberty, infertility, recurrent miscarriages, or neurological symptoms like neuropathy and “brain fog.” The panel helps clarify if these issues are due to celiac disease and guides further management.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Rubio-Tapia, A., Hill, I. D., Semrad, C., Kelly, C. P., & Lebwohl, B. (2023). American College of Gastroenterology guidelines update: Diagnosis and management of celiac disease. The American Journal of Gastroenterology, 118(1), 59-76. https://doi.org/10.14309/ajg.0000000000002075
- Chang, D., Wong, M., Cardenas, M. C., Stahl, M. G., Liu, E., Caplan, M., Gidrewicz, D., King, J. A., Turner, J. M., Leonard, M. M., Lee, D., Pacheco, M. C., Dickerson, J., Raber, C., Badalyan, V., Chugh, A., Setty, M., Baek, C., Singh, A., ... Absah, I. (2025). Positive predictive value of tissue transglutaminase IgA for celiac disease. Pediatrics, 156(3), e2025070897. https://doi.org/10.1542/peds.2025-070897
- Alexandre, L., & Chan, S. S. M. (2021). Iron deficiency: A modern primer to diagnosis and management. Current Opinion in Gastroenterology, 37(2), 121-127. https://doi.org/10.1097/MOG.0000000000000702
- Zintzaras, E., & Germenis, A. E. (2006). Performance of antibodies against tissue transglutaminase for the diagnosis of celiac disease: Meta-analysis. Clinical and Vaccine Immunology, 13(2), 187-192. https://doi.org/10.1128/CVI.13.2.187-192.2006
- El Brihi, J., & Pathak, S. (2024). Normal and abnormal complete blood count with differential. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK604207/
.avif)
.svg)
.svg)
